BiotechTube
Home/MitoSense/Brent Segal, PhD
BS

Brent Segal, PhD

Chief Executive Officer

MitoSense

Therapeutic Areas

Neurodegenerative Diseases

MitoSense Pipeline

DrugIndicationPhase
MOT™ for ALSAmyotrophic Lateral Sclerosis (ALS)Pre-clinical
MOT™ PlatformAlzheimer's Disease, Parkinson's Disease, Huntington's Disease, Multiple SclerosisResearch/Discovery

Leadership Team at MitoSense

VH
Van Hipp
Chairman
CB
Catherine Baucom, MD, PhD
Chief Medical Officer
XP
Xian Peng Jiang
Chief Scientific Officer
RW
Rick Waldo
Board Member
View full MitoSense profile